<p>Terns Pharmaceuticals, Inc.（纳斯达克代码：TERN - 获取免费报告）获得了覆盖该公司的十五位分析师的共识推荐为 “持有”，MarketBeat.com 报道称。一位股票研究分析师给予该股票 “卖出” 评级，十位分析师给予 “持有” 评级，三位分析师给予 “买入” 评级，还有一位分析师给予 “强烈买入” 评级。在过去一年中，覆盖该股票的经纪人给出的平均一年目标价格为 55.1364 美元。</p>
<p>获取 <strong>Terns Pharmaceuticals</strong> 的提醒：</p>
<p>TERN 已成为多份研究报告的主题。威廉·布莱尔在 4 月 7 日的报告中将 Terns Pharmaceuticals 的股票评级从 “强烈买入” 下调至 “持有”。公民 Jmp 在 3 月 26 日的报告中将 Terns Pharmaceuticals 的股票评级从 “市场表现优于大盘” 下调至 “持有”。BMO Capital Markets 在 3 月 26 日的报告中将 Terns Pharmaceuticals 的股票评级从 “强烈买入” 下调至 “持有”。TD Cowen 在 3 月 26 日的报告中将 Terns Pharmaceuticals 的股票评级从 “买入” 下调至 “持有”，并设定了 53.00 美元的目标价格。最后，Weiss Ratings 在 3 月 27 日的报告中重新发布了 Terns Pharmaceuticals 的 “卖出（e+）” 评级。</p>
<p><strong>查看我们最新的 Terns Pharmaceuticals 股票报告</strong></p>
<h2>内部人士下注</h2>
<p>在其他消息中，首席执行官艾米·L·巴罗（Amy L. Burroughs）在 3 月 16 日的交易中出售了 14,583 股公司的股票。股票以平均价格 46.71 美元出售，总价值为 681,171.93 美元。出售后，首席执行官直接持有 288,976 股公司的股票，价值约为 13,498,068.96 美元。这代表其持股比例下降了 4.80%。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站获取。此外，内部人士埃米尔·库里亚科斯（Emil Kuriakose）在 4 月 1 日的交易中出售了 942 股公司的股票。股票以平均价格 52.75 美元出售，总交易额为 49,690.50 美元。出售完成后，该内部人士直接持有 105,673 股公司股票，价值约为 5,574,250.75 美元。这代表其持股比例下降了 0.88%。该交易的披露信息可在 SEC 文件中找到。在过去的九十天里，内部人士出售了价值 1,302,370 美元的 30,108 股公司股票。内部人士持有公司股票的比例为 1.50%。</p>
<h2>机构投资者对 Terns Pharmaceuticals 的看法</h2>
<p>一些机构投资者最近调整了对公司的持股。摩根士丹利在第四季度将其在 Terns Pharmaceuticals 的股份增加了 4.7%。摩根士丹利目前持有 7,945,608 股公司股票，价值 321,003,000 美元，此前在上个季度购买了额外的 356,513 股。Commodore Capital LP 在第三季度购买了价值 42,807,000 美元的 Terns Pharmaceuticals 新股份。Adage Capital Partners GP L.L.C. 在第四季度将其在 Terns Pharmaceuticals 的股份增加了 40.9%。Adage Capital Partners GP L.L.C. 目前持有 5,550,000 股公司股票，价值 224,220,000 美元，此前在上个季度购买了额外的 1,611,000 股。先锋集团（Vanguard Group Inc.）在第四季度将其在 Terns Pharmaceuticals 的股份增加了 21.1%。先锋集团目前持有 5,523,948 股公司股票，价值 223,167,000 美元，此前在上个季度购买了额外的 964,031 股。最后，Vestal Point Capital LP 在第四季度购买了价值 181,800,000 美元的 Terns Pharmaceuticals 新股份。98.26% 的股票由机构投资者持有。</p>
<h2>Terns Pharmaceuticals 价格表现</h2>
<p>TERN 周二开盘价为 52.97 美元。Terns Pharmaceuticals 的 52 周低点为 2.65 美元，52 周高点为 53.19 美元。该公司的市值为 61.2 亿美元，市盈率为 -51.42，贝塔值为 -0.37。公司的 50 日移动平均价格为 48.93 美元，200 日移动平均价格为 36.96 美元。</p>
<p>Terns Pharmaceuticals（纳斯达克代码：TERN - 获取免费报告）最后一次发布财报是在 3 月 30 日，报告显示该公司本季度每股收益为（0.24）美元，超出分析师共识预期的（0.30）美元 0.06 美元。作为一个整体，股票研究分析师预测 Terns Pharmaceuticals 在本年度将发布 -1.21 的每股收益。</p>
<h2>关于 Terns Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Terns Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于开发用于治疗慢性肝病和其他严重疾病的口服小分子疗法。该公司的研发工作集中在旨在解决进展性肝病的根本原因的新机制上，包括炎症、纤维化和代谢失调。通过推进可以口服给药的靶向化合物，Terns 旨在为患者提供比注射或生物疗法更方便和有效的治疗选择。</p>
<p>该公司的产品管线包含多个处于不同临床和前临床评估阶段的候选药物。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Terns Pharmaceuticals</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBURZTeW1ib2w9VEVSTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBURZTeW1ib2w9VEVSTg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Terns Pharmaceuticals 吗？</h2>
<p>在你考虑投资 Terns Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Terns Pharmaceuticals 并不在名单上。</p>
<p>虽然 Terns Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TERN

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

标普生物技术 3 倍做多 - Direxion

2 倍做多纳斯达克生物技术 ETF - ProShares

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

生物科技 ETF - VanEck Vectors

<p>Terns Pharmaceuticals, Inc.（纳斯达克代码：TERN）获得了十五位分析师的 “持有” 共识推荐。具体分布为一位卖出、十位持有、三位买入和一位强烈买入推荐。平均一年目标价为 55.14 美元。近期内部人士交易包括首席执行官 Amy L. Burroughs 出售了 14,583 股，Emil Kuriakose 出售了 942 股。机构投资者持有 98.26% 的股份。Terns 的市值为 61.2 亿美元，报告每股收益为（0.24 美元），超出预期。该股票开盘价为 52.97 美元，52 周价格区间为 2.65 美元至 53.19 美元</p>

<p>Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has earned a consensus recommendation of &#34;Hold&#34; from the fifteen analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, ten have assigned a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $55.1364.</p>
<div class="lb-trans"><p>Terns Pharmaceuticals, Inc.（纳斯达克代码：TERN - 获取免费报告）获得了覆盖该公司的十五位分析师的共识推荐为 “持有”，MarketBeat.com 报道称。一位股票研究分析师给予该股票 “卖出” 评级，十位分析师给予 “持有” 评级，三位分析师给予 “买入” 评级，还有一位分析师给予 “强烈买入” 评级。在过去一年中，覆盖该股票的经纪人给出的平均一年目标价格为 55.1364 美元。</p>
</div><p>Get <strong>Terns Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Terns Pharmaceuticals</strong> 的提醒：</p>
</div><p>TERN has been the topic of a number of research reports. William Blair lowered shares of Terns Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, April 7th. Citizens Jmp lowered shares of Terns Pharmaceuticals from a &#34;market outperform&#34; rating to a &#34;hold&#34; rating in a report on Thursday, March 26th. BMO Capital Markets lowered shares of Terns Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Thursday, March 26th. TD Cowen lowered shares of Terns Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating and set a $53.00 target price on the stock. in a report on Thursday, March 26th. Finally, Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of Terns Pharmaceuticals in a report on Friday, March 27th.</p>
<div class="lb-trans"><p>TERN 已成为多份研究报告的主题。威廉·布莱尔在 4 月 7 日的报告中将 Terns Pharmaceuticals 的股票评级从 “强烈买入” 下调至 “持有”。公民 Jmp 在 3 月 26 日的报告中将 Terns Pharmaceuticals 的股票评级从 “市场表现优于大盘” 下调至 “持有”。BMO Capital Markets 在 3 月 26 日的报告中将 Terns Pharmaceuticals 的股票评级从 “强烈买入” 下调至 “持有”。TD Cowen 在 3 月 26 日的报告中将 Terns Pharmaceuticals 的股票评级从 “买入” 下调至 “持有”，并设定了 53.00 美元的目标价格。最后，Weiss Ratings 在 3 月 27 日的报告中重新发布了 Terns Pharmaceuticals 的 “卖出（e+）” 评级。</p>
</div><p><strong>View Our Latest Stock Report on Terns Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Terns Pharmaceuticals 股票报告</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, CEO Amy L. Burroughs sold 14,583 shares of the company's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $46.71, for a total value of $681,171.93. Following the sale, the chief executive officer directly owned 288,976 shares of the company's stock, valued at approximately $13,498,068.96. This represents a 4.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Emil Kuriakose sold 942 shares of the company's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $52.75, for a total transaction of $49,690.50. Following the completion of the sale, the insider directly owned 105,673 shares in the company, valued at approximately $5,574,250.75. This represents a 0.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 30,108 shares of company stock worth $1,302,370. Insiders own 1.50% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席执行官艾米·L·巴罗（Amy L. Burroughs）在 3 月 16 日的交易中出售了 14,583 股公司的股票。股票以平均价格 46.71 美元出售，总价值为 681,171.93 美元。出售后，首席执行官直接持有 288,976 股公司的股票，价值约为 13,498,068.96 美元。这代表其持股比例下降了 4.80%。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站获取。此外，内部人士埃米尔·库里亚科斯（Emil Kuriakose）在 4 月 1 日的交易中出售了 942 股公司的股票。股票以平均价格 52.75 美元出售，总交易额为 49,690.50 美元。出售完成后，该内部人士直接持有 105,673 股公司股票，价值约为 5,574,250.75 美元。这代表其持股比例下降了 0.88%。该交易的披露信息可在 SEC 文件中找到。在过去的九十天里，内部人士出售了价值 1,302,370 美元的 30,108 股公司股票。内部人士持有公司股票的比例为 1.50%。</p>
</div><h2>Institutional Investors Weigh In On Terns Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Terns Pharmaceuticals 的看法</h2>
</div><p>A number of institutional investors have recently modified their holdings of the company. Morgan Stanley boosted its stake in shares of Terns Pharmaceuticals by 4.7% in the 4th quarter. Morgan Stanley now owns 7,945,608 shares of the company's stock valued at $321,003,000 after purchasing an additional 356,513 shares during the last quarter. Commodore Capital LP bought a new stake in shares of Terns Pharmaceuticals in the 3rd quarter valued at $42,807,000. Adage Capital Partners GP L.L.C. boosted its stake in shares of Terns Pharmaceuticals by 40.9% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,550,000 shares of the company's stock valued at $224,220,000 after purchasing an additional 1,611,000 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Terns Pharmaceuticals by 21.1% in the 4th quarter. Vanguard Group Inc. now owns 5,523,948 shares of the company's stock valued at $223,167,000 after purchasing an additional 964,031 shares during the last quarter. Finally, Vestal Point Capital LP bought a new stake in shares of Terns Pharmaceuticals in the 4th quarter valued at $181,800,000. 98.26% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些机构投资者最近调整了对公司的持股。摩根士丹利在第四季度将其在 Terns Pharmaceuticals 的股份增加了 4.7%。摩根士丹利目前持有 7,945,608 股公司股票，价值 321,003,000 美元，此前在上个季度购买了额外的 356,513 股。Commodore Capital LP 在第三季度购买了价值 42,807,000 美元的 Terns Pharmaceuticals 新股份。Adage Capital Partners GP L.L.C. 在第四季度将其在 Terns Pharmaceuticals 的股份增加了 40.9%。Adage Capital Partners GP L.L.C. 目前持有 5,550,000 股公司股票，价值 224,220,000 美元，此前在上个季度购买了额外的 1,611,000 股。先锋集团（Vanguard Group Inc.）在第四季度将其在 Terns Pharmaceuticals 的股份增加了 21.1%。先锋集团目前持有 5,523,948 股公司股票，价值 223,167,000 美元，此前在上个季度购买了额外的 964,031 股。最后，Vestal Point Capital LP 在第四季度购买了价值 181,800,000 美元的 Terns Pharmaceuticals 新股份。98.26% 的股票由机构投资者持有。</p>
</div><h2>Terns Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Terns Pharmaceuticals 价格表现</h2>
</div><p>TERN opened at $52.97 on Tuesday. Terns Pharmaceuticals has a fifty-two week low of $2.65 and a fifty-two week high of $53.19. The firm has a market capitalization of $6.12 billion, a price-to-earnings ratio of -51.42 and a beta of -0.37. The company's 50 day moving average price is $48.93 and its two-hundred day moving average price is $36.96.</p>
<div class="lb-trans"><p>TERN 周二开盘价为 52.97 美元。Terns Pharmaceuticals 的 52 周低点为 2.65 美元，52 周高点为 53.19 美元。该公司的市值为 61.2 亿美元，市盈率为 -51.42，贝塔值为 -0.37。公司的 50 日移动平均价格为 48.93 美元，200 日移动平均价格为 36.96 美元。</p>
</div><p>Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last posted its earnings results on Monday, March 30th. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.06. As a group, equities research analysts predict that Terns Pharmaceuticals will post -1.21 EPS for the current year.</p>
<div class="lb-trans"><p>Terns Pharmaceuticals（纳斯达克代码：TERN - 获取免费报告）最后一次发布财报是在 3 月 30 日，报告显示该公司本季度每股收益为（0.24）美元，超出分析师共识预期的（0.30）美元 0.06 美元。作为一个整体，股票研究分析师预测 Terns Pharmaceuticals 在本年度将发布 -1.21 的每股收益。</p>
</div><h2>About Terns Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Terns Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company's research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.</p>
<div class="lb-trans"><p>Terns Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于开发用于治疗慢性肝病和其他严重疾病的口服小分子疗法。该公司的研发工作集中在旨在解决进展性肝病的根本原因的新机制上，包括炎症、纤维化和代谢失调。通过推进可以口服给药的靶向化合物，Terns 旨在为患者提供比注射或生物疗法更方便和有效的治疗选择。</p>
</div><p>The company's pipeline features several candidates in various stages of preclinical and clinical evaluation.</p>
<div class="lb-trans"><p>该公司的产品管线包含多个处于不同临床和前临床评估阶段的候选药物。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Terns Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Terns Pharmaceuticals</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVSTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=TERN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Terns Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Terns Pharmaceuticals 吗？</h2>
</div><p>Before you consider Terns Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Terns Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Terns Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Terns Pharmaceuticals 并不在名单上。</p>
</div><p>While Terns Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Terns Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Recommendation of "Hold" from Analysts

Market Beat

Terns Pharmaceuticals

蒙特利尔银行

Toronto Dominion Bank

摩根士丹利

The Vanguard Group, Inc.

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Terns Pharmaceuticals, Inc.（纳斯达克股票代码：TERN）被分析师给予 “持有” 的平均建议